Eight months after receiving approval for Erbitux in colorectal cancer, ImClone Systems Inc. and Bristol-Myers Squibb Co. set out on another Phase III program for the drug, this time targeting non-small-cell lung cancer. (BioWorld Today)
It's one thing to report drug production problems and suffer a stock drop - that happens often in the biotech sector - but it's quite another to push the entire U.S. toward a public health crisis. Last week, Chiron Corp. had the distinct dishonor of doing both.
RSS